Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms.
about
Breakthrough cancer pain: review of prevalence, characteristics and managementAn evaluation of total disintegration time for three different doses of sublingual fentanyl tablets in patients with breakthrough painBreakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.Review article: palliative care in gynecologic oncology.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: multicenter prospective observational study.Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats.Nociception and inflammatory hyperalgesia evaluated in rodents using infrared laser stimulation after Trpv1 gene knockout or resiniferatoxin lesionCorrelations between plasma endothelin-1 levels and breakthrough pain in patients with cancer.Breakthrough cancer pain - still a challengeDesign, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.Recognition and diagnosis of breakthrough pain.Canadian recommendations for the management of breakthrough cancer pain.The rationale for a multimodal approach in the management of breakthrough cancer pain: a review.Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant painCancer pain--progress and ongoing issues in Europe.Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.Fentanyl buccal tablet for breakthrough cancer pain: why titrate?Management of pain in the elderly at the end of life.Ketamine in pain management.The pharmacoeconomics of breakthrough cancer pain.Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.Spinal neuronal correlates of tapentadol analgesia in cancer pain: a back-translational approach.Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies.Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study.Fentanyl pectin nasal spray for breakthrough cancer pain.Physicians' Practice, Attitudes Toward, and Knowledge of Cancer Pain Management in China.Breakthrough Cancer Pain Is Associated with Spinal Gap Junction Activation via Regulation of Connexin 43 in a Mouse Model.Use of nasal fentanyl for cancer pain: A pharmacoepidemiological study.Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain.Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.Cancer pain physiology.Breakthrough pain in patients referred to pain clinics: the Italian pain network retrospective study.Breakthrough pain in opioid-treated chronic non-malignant pain patients referred to a multidisciplinary pain centre: a preliminary study.Standardized treatment of Chinese medicine decoction for cancer pain patients with opioid-induced constipation: a multi-center prospective randomized controlled study.Adult cancer pain.[Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].
P2860
Q24633771-534D0ACB-FCFC-430D-814D-BCFBF917404CQ33938312-34CCE755-D19F-4486-B02B-E5F3683A2A2EQ33970064-6CB0AD4C-0BC3-4D97-83D6-5F4C839ADA3AQ34156710-EB0DD981-1503-498A-8675-C56B991F87E8Q34635638-8194E1C7-C41D-4DA3-9645-7A9C7DB24042Q35795558-0891C568-C153-483C-9F9E-119C2EC7CFEAQ35874744-4DF2B016-01A9-45AA-9C6A-7AA9AAF3B177Q36052397-561B54BE-F70F-4130-BB9C-555BF4336488Q36368292-6F8FAAA4-33D0-4F85-B0BA-967F2FF64053Q36429904-73DD797C-A437-468F-A75B-5E998C19A3D7Q36480105-DD4AFB36-C64A-4CAB-A575-3913C0FF5F52Q36728951-AB42B267-67D3-4392-8CD8-7E767F3050F5Q36807866-86E3095C-37D6-4388-BF23-C54760BCFBF6Q36854479-0C2C3CB5-7B9B-4A0D-926F-CE960287649AQ37593370-DC5341E0-2651-4686-9E79-8BCC51800F53Q37644452-410D9F0E-2F2C-4EFB-9E72-E4FA9520A886Q37774349-C3255C6B-4E72-4D59-906A-40CEBAAF081AQ37784261-91D7C9DE-7DB6-44D4-8726-90693FBE8447Q37998511-548DA323-962D-4BCB-A304-FBB39CE83258Q38105649-D1C1D092-8445-452A-86C0-6518E21F1020Q38108027-C25DD1B8-3E1B-40DA-9E5F-8908E3FAB752Q38599605-85426A93-8FA1-4B42-BA81-92059A0F238DQ38985991-8C3FC375-160C-4C10-8E4A-CDCFF64E056BQ39150765-5CA373DF-25C5-4D32-B42E-A8F49125DC0DQ39253677-CF99100A-00E8-4920-B7F8-06EAB21B73FCQ39268873-76C5E1B6-8D12-4C35-9737-0B470C596F3CQ39294172-28B683DE-3FA2-4B40-9E5C-B6653A4FF382Q39652268-B62D218D-14D0-47A5-AFB6-5D4C35C87F7CQ40789765-FE9A3068-3441-47FB-B096-B841D1AB57CAQ41024056-FB47221C-E0EC-4C48-B7F8-4FA5150A0A80Q41241421-F58C1233-D318-4A0E-BD84-022D55E78BC0Q41936879-9A2C87A5-B827-45F1-B667-6578E2C228EDQ42230948-63501715-888F-4C19-A758-EE9B5BB167A8Q42659408-ECBF907A-0493-44CA-8465-EDF6B06DCBD7Q43205303-A6F78605-517B-4CDF-8E78-B5109C7836FEQ43568437-99BCCCBF-83DF-406B-B861-E6AD63B5D6BCQ44332137-BDD73238-66DD-4EF3-AC6F-D02016A6C103Q44345622-FA965E86-3B51-4A69-AE68-6690C1DED11AQ44426953-E8592DEA-577A-4275-A88A-9B0FBFBBC923Q45906120-9CA58891-91A7-4E3F-8DEB-561B6DED5906
P2860
Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Breakthrough pain in malignant ...... haracteristics and mechanisms.
@ast
Breakthrough pain in malignant ...... haracteristics and mechanisms.
@en
type
label
Breakthrough pain in malignant ...... haracteristics and mechanisms.
@ast
Breakthrough pain in malignant ...... haracteristics and mechanisms.
@en
prefLabel
Breakthrough pain in malignant ...... haracteristics and mechanisms.
@ast
Breakthrough pain in malignant ...... haracteristics and mechanisms.
@en
P2093
P2860
P50
P1476
Breakthrough pain in malignant ...... haracteristics and mechanisms.
@en
P2093
Kristina B Svendsen
Per Sjogren
Peter Strang
Sigurdur Arnason
Staffan Arnér
Steen Andersen
Tarja Heiskanen
Ulf E Kongsgaard
P2860
P304
P356
10.1016/J.EJPAIN.2004.06.001
P577
2005-04-01T00:00:00Z